Brii Biosciences introduces its BRiSC siRNA platform to expand its therapeutic pipeline, targeting metabolic diseases through advanced dual-targeting medicine development.
Brii Biosciences has launched its proprietary BRiSC™ platform, a strategic move aimed at developing dual-targeting siRNA medicines. By focusing on metabolic dysfunctions and complex comorbidities, the company is positioning itself to address multi-pathway disease biology, though the lack of specific financial guidance or clinical timelines remains a notable gap in the disclosure.
It is a proprietary discovery platform developed by Brii Biosciences to advance next-generation dual-targeting siRNA medicines.
The initial focus is on prevalent metabolic dysfunctions characterized by complex disease biology and overlapping comorbidities.
Brii Biosciences has unveiled its proprietary BRiSC siRNA discovery platform, aiming to accelerate the development of dual-targeting medicines. The initiative focuses on addressing complex metabolic dysfunctions by modulating multiple disease pathways simultaneously.
The BRiSC platform is designed to discover and develop dual-targeting siRNA medicines, specifically focusing on complex metabolic diseases.